Core Insights - The U.S. anatomic pathology market is projected to reach an estimated revenue of $37.1 billion in 2025, with a long-term annual growth rate of 10.1% driven primarily by increased molecular oncology testing, particularly minimal residual disease (MRD) testing for cancer treatment [3][4]. Market Trends - The report highlights significant changes in the U.S. anatomic pathology market, including the introduction of artificial intelligence tools that enhance pathologist productivity and increased utilization management by private payers, alongside ongoing reimbursement pressures [4][5]. - New higher-priced molecular oncology tests, such as next-generation sequencing for tumor mutation profiling and MRD testing, are expected to counterbalance price and volume pressures on routine pathology tests [5]. Challenges - The primary challenge facing the market comes from third-party payers implementing prior authorization policies and laboratory benefit management programs aimed at reducing the utilization of anatomic pathology services and genetic tests for cancer [6]. Report Features - The report includes over 100 charts and graphs, detailed market size and growth rates, estimates for market subsets like uropathology, dermatopathology, and gastrointestinal pathology, and an in-depth analysis of the molecular oncology testing market [6]. - It also provides Medicare claims data for over 60 key pathology codes, trends in cervical cancer testing, and a detailed analysis of the emerging digital pathology and AI market [6].